enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Pembrolizumab - Wikipedia

   en.wikipedia.org/wiki/Pembrolizumab

   Micrograph showing a PD-L1 positive non-small cell lung carcinoma. PD-L1 immunostain. As of 2019, pembrolizumab is used via intravenous infusion to treat inoperable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC) in certain situations, as a first-line treatment for metastatic bladder cancer in patients who cannot receive cisplatin-based chemotherapy and have high levels ...

3. Merck's Keytruda gets FDA nod for expanded use in lung cancer

   www.aol.com/news/mercks-keytruda-gets-u-fdas...

   The U.S. health regulator's approval extends Keytruda's use in combination with chemotherapy as a treatment given before surgery to shrink the size of the tumor in patients. The U.S. drugmaker is ...

4. Merck's Keytruda Secures First FDA-Approval For Rare Form ...

   www.aol.com/mercks-keytruda-secures-first-fda...

   Phase 3 KEYNOTE-867 trial evaluating Keytruda (pembrolizumab) in combination with stereotactic body radiotherapy for stage I or II non-small cell lung cancer, including those who are medically ...

5. Merck's Keytruda Improves 5-Year Survival in Lung Cancer - AOL

   www.aol.com/news/mercks-keytruda-improves-5...

   Merck (MRK) presents longest follow-up data for Keytruda in advance lung cancer at ASCO 2019. The five-year overall survival rates in the Keytruda arm are better than historical rates

6. Merck scraps two late-stage trials of cancer drug Keytruda

   www.aol.com/news/merck-scraps-two-stage-trials...

   The company has been seeking to test Keytruda in combination with other treatments and expand its use in types of cancers not yet treated by immunotherapies, as the drug faces loss of patent ...

7. PD-1 and PD-L1 inhibitors - Wikipedia

   en.wikipedia.org/wiki/PD-1_and_PD-L1_inhibitors

   Pembrolizumab (Keytruda, formerly MK-3475 and lambrolizumab) was developed by Merck and first approved by the Food and Drug Administration in 2014 for the treatment of melanoma. It was later approved for metastatic non-small cell lung cancer and head and neck squamous cell carcinoma .